# Tevogen Bio Holdings Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Tevogen Bio Holdings Inc.).

## Overview

Tevogen Bio Holdings Inc. is a U.S.-based biotechnology company focused on developing T-cell therapies and related platform technologies for infectious diseases, cancer, and neurological disorders. Its core programs include TVGN 489 and the ExacTcell technology platform, supported by Tevogen.AI and a portfolio of intellectual property.

## Products & services

• TVGN 489 cell therapy candidate for infectious diseases
• ExacTcell T-cell engineering platform
• Tevogen.AI drug discovery and development tools
• Preclinical and clinical-stage immunotherapy programs
• Intellectual property licensing and patent portfolio

- **Clinical-stage product candidates** (0%) — Cell therapy candidates under preclinical and clinical development, including TVGN 489.
- **Platform technology** (0%) — ExacTcell technology used to identify and develop antigen-specific T-cell therapies.
- **AI-enabled discovery tools** (0%) — Tevogen.AI tools used to support target selection, discovery, and development workflows.
- **Intellectual property** (0%) — Issued patents, pending applications, and trademarks tied to the company’s technologies.

- TVGN 489 cell therapy candidate for infectious diseases
- ExacTcell T-cell engineering platform
- Tevogen.AI drug discovery and development tools
- Preclinical and clinical-stage immunotherapy programs
- Intellectual property licensing and patent portfolio

## Customers

Tevogen Bio does not yet have commercial product customers; its near-term end users are expected to be patients treated through hospitals, clinics, and specialty providers once products are approved. In the development phase, the company’s direct counterparties are research sites, contract research organizations, manufacturing partners, and potential commercial partners or payors.

- **Patients** (primary) — End beneficiaries of TVGN 489 and other future cell therapy candidates for infectious, oncology, or neurological indications.
- **Hospitals and specialty providers** (primary) — Clinical settings that would administer approved therapies and manage patient access.
- **Clinical research organizations and trial sites** (secondary) — Buy development services and support trial execution, data collection, and regulatory studies.
- **Manufacturing and supply partners** (secondary) — Provide lab, process development, and manufacturing capabilities needed for cell therapy scale-up.
- **Potential commercial partners and payors** (emerging) — Relevant for future licensing, reimbursement, and market access once products are commercialized.

- Patients with infectious diseases, cancer, or neurological disorders
- Hospitals and specialty clinics that would administer approved therapies
- Clinical trial sites and CROs supporting development work
- Manufacturing and supply partners for cell therapy production
- Potential payors and reimbursement stakeholders for future commercialization

## Geography

Tevogen Bio is headquartered in the United States and conducts its research, intellectual property, and facility operations there. The company’s disclosed footprint centers on New Jersey, with prior laboratory activity in Philadelphia, and its commercial exposure is currently concentrated in the U.S. healthcare and regulatory environment.

- Headquartered and operated in the United States
- Research and laboratory operations centered in New Jersey
- Former laboratory facility in Philadelphia, Pennsylvania
- U.S. patent portfolio and trademark filings
- Future commercialization would initially depend on U.S. approvals

## Strategy

Tevogen Bio’s strategy is to advance its cell therapy pipeline through preclinical work, clinical trials, and regulatory development while building the manufacturing capability needed for eventual commercialization. It also seeks to extend its platform through ExacTcell and Tevogen.AI, using intellectual property and technology development to broaden its pipeline and support future partnering opportunities.

- **Advance TVGN 489 development** (short-term) — Clinical and regulatory progress is required before any product revenue can be generated.
- **Build manufacturing capability** (short-term) — Cell therapies require specialized production, quality control, and supply chain infrastructure.
- **Broaden the pipeline with platform technologies** (medium-term) — ExacTcell and Tevogen.AI can support additional candidates and reduce dependence on one program.
- **Protect intellectual property** (long-term) — Patents and trademarks are central to exclusivity and future partnering value.

- Advance TVGN 489 through clinical development and regulatory steps
- Expand the pipeline using ExacTcell and Tevogen.AI
- Build manufacturing infrastructure for cell therapy production
- Develop commercialization capabilities for future launch
- Protect and extend the patent portfolio around core technologies

## Risks

Tevogen Bio is a development-stage biotechnology company with no product revenue to date, so its business depends on successful clinical, regulatory, and manufacturing execution. The company also faces financing, listing, and litigation-related risks typical of early-stage public biopharma issuers, along with scientific and competitive uncertainty around cell therapy development.

- **No commercial revenue yet** [high] — The company depends on future approval and launch of TVGN 489 or another candidate before sales begin.
- **Clinical and regulatory failure** [critical] — Drug candidates may not demonstrate safety, efficacy, or manufacturability required for approval.
- **Manufacturing execution risk** [high] — Cell therapy production requires specialized infrastructure, quality systems, and supply reliability.
- **Nasdaq listing and liquidity risk** [high] — Failure to maintain listing standards could reduce trading liquidity and investor access.
- **Legal and transaction-related uncertainty** [medium] — The company disclosed potential legal proceedings related to the business combination.

- No product revenue until approval and commercialization
- Clinical trial and regulatory outcomes may not support approval
- Manufacturing scale-up for cell therapies is complex and costly
- Nasdaq listing compliance and trading liquidity are a concern
- IP and legal disputes could affect the business combination or assets

## Accounting

Key accounting judgments include fair value estimates for common stock and convertible notes, stock-based compensation, and accrued expenses, all of which can materially affect reported results for a development-stage company. Lease accounting is also important because the company expanded its Warren, New Jersey facility and consolidated operations there, making operating lease commitments a meaningful balance-sheet and cash-flow item.

- **Fair value measurements** — Reported earnings and balance sheet values
- **Stock-based compensation** — Operating expenses and dilution
- **Accrued expenses** — Quarterly expense recognition
- **Operating leases** — Balance sheet, cash flow, and occupancy costs

- Fair value of common stock affects equity-related measurements
- Convertible note valuation can create non-cash gains or losses
- Stock-based compensation is a major estimate in early-stage biotech
- Operating lease accounting affects liabilities and future cash commitments
- Capitalized vs expensed R&D is limited by GAAP and affects losses

---

*Last updated: 2026-04-29T05:03:32.385230+00:00*